Hart Moss, MD
Cornea and External Diseases Specialist · Greenfield, WINPI 1437393675
Payments from drug & device makers
Across 96 payments — averaging $29.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$551
- Alcon$539
- Rxsight Inc$484
- Ocular Therapeutix, Inc.$260
- AbbVie$219
- NEW World Medical,inc.$195
- plus $540 from 13 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$2,65095%
- Education$803%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 12 | $551 |
| Alcon | 11 | $539 |
| Rxsight Inc | 11 | $484 |
| Ocular Therapeutix, Inc. | 14 | $260 |
| AbbVie(2 entities) | 8 | $219 |
| NEW World Medical,inc. | 13 | $195 |
| Dompe US, Inc. | 5 | $98 |
| Bausch & Lomb Americas Inc. | 5 | $92 |
| Kala Pharmaceuticals, Inc. | 4 | $80 |
| Rayner Intraocular Lenses Limited | 3 | $59 |
| The Cameron-ehlen Group, Inc. | 1 | $47 |
| Novartis | 2 | $40 |
| Harrow Eye, LLC | 1 | $23 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| Oyster Point Pharma, Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sight Sciences, Inc. | 1 | $16 |
| Amgen | 1 | $14 |
| Biotissue Holdings Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$249
- RXSIGHT INJECTOR CARTRIDGE$249
- RXSIGHT INJECTOR HANDPIECE$249
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$249
- Clareon$217
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$137
- iStent$118
- KXL System$118
- Photrexa$118
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$116
- iAccess Precision Blade$116
- LIGHT ADJUSTABLE LENS (LAL)$112
How this compares
Too few cornea and external diseases specialist providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $340,437 |
| RestasisCyclosporine | 57 | $74,401 |
| XiidraLifitegrast | 20 | $17,891 |
| Cyclosporine | 24 | $17,469 |
| Fluorometholone | 185 | $11,778 |
| Prednisolone Acetate | 327 | $11,614 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 43 | $11,375 |
| TyrvayaVarenicline Tartrate | 13 | $8,261 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $7,306 |
| Loteprednol Etabonate | 35 | $5,515 |
| Alphagan PBrimonidine Tartrate | 11 | $5,448 |
| RocklatanNetarsudil Mesylat/Latanoprost | 13 | $5,302 |
| Latanoprost | 367 | $3,859 |
| Brinzolamide | 17 | $3,759 |
| Lotemax SmLoteprednol Etabonate | 13 | $3,373 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $98 | $340,43712 claims |
| AbbVieRestasis, Combigan, Alphagan P | $219 | $87,15599 claims |
| Bausch & Lomb Americas Inc.Xiidra | $92 | $17,89120 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $21 | $8,26113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Wisconsinon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Greenfield
- Vinicius Silbiger de StefanoMilwaukee$2K
- Nicole Anderson-WeissMadison$1K
- Thomas AlprenMilwaukee$696
- Afua ShinWausau$473
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.